DE60213845D1 - Kombinationstherapie mit zd6474 und einem taxan - Google Patents

Kombinationstherapie mit zd6474 und einem taxan

Info

Publication number
DE60213845D1
DE60213845D1 DE60213845T DE60213845T DE60213845D1 DE 60213845 D1 DE60213845 D1 DE 60213845D1 DE 60213845 T DE60213845 T DE 60213845T DE 60213845 T DE60213845 T DE 60213845T DE 60213845 D1 DE60213845 D1 DE 60213845D1
Authority
DE
Germany
Prior art keywords
taxan
combination therapy
therapy
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213845T
Other languages
English (en)
Other versions
DE60213845T2 (de
Inventor
Robert Wedge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60213845D1 publication Critical patent/DE60213845D1/de
Publication of DE60213845T2 publication Critical patent/DE60213845T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60213845T 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan Expired - Lifetime DE60213845T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0126879 2001-11-08
GBGB0126879.6A GB0126879D0 (en) 2001-11-08 2001-11-08 Combination therapy
PCT/GB2002/005021 WO2003039551A1 (en) 2001-11-08 2002-11-06 Combination therapy comprising zd6474 and a taxane

Publications (2)

Publication Number Publication Date
DE60213845D1 true DE60213845D1 (de) 2006-09-21
DE60213845T2 DE60213845T2 (de) 2007-03-29

Family

ID=9925430

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213845T Expired - Lifetime DE60213845T2 (de) 2001-11-08 2002-11-06 Kombinationstherapie mit zd6474 und einem taxan

Country Status (23)

Country Link
US (2) US20050043395A1 (de)
EP (1) EP1446124B1 (de)
JP (1) JP4694127B2 (de)
KR (1) KR100959607B1 (de)
CN (1) CN1298328C (de)
AR (1) AR037346A1 (de)
AT (1) ATE335488T1 (de)
AU (1) AU2002337382B2 (de)
BR (1) BR0213906A (de)
CA (1) CA2464758C (de)
CY (1) CY1106259T1 (de)
DE (1) DE60213845T2 (de)
DK (1) DK1446124T3 (de)
ES (1) ES2269769T3 (de)
GB (1) GB0126879D0 (de)
HK (1) HK1068546A1 (de)
IL (2) IL161744A0 (de)
MX (1) MXPA04004355A (de)
NO (1) NO328048B1 (de)
NZ (1) NZ532525A (de)
PT (1) PT1446124E (de)
WO (1) WO2003039551A1 (de)
ZA (1) ZA200403455B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004366A (es) 1999-11-05 2002-11-07 Astrazeneca Ab Derivados de quinazolina como inhibidores vegf.
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ES2267748T3 (es) * 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
EP1474420B1 (de) 2002-02-01 2012-03-14 AstraZeneca AB Chinazoline verbindungen
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
SI1562955T1 (sl) 2002-11-04 2008-06-30 Astrazeneca Ab Derivati kinazolina kot inhibitorji Src-triozin kinaze
DK1592423T3 (da) * 2003-02-13 2011-06-27 Astrazeneca Ab Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
MXPA06000114A (es) * 2003-07-10 2006-04-27 Astrazeneca Ab Uso del derivado de quinazolina zd6474 combinado con compuestos de platino y, opcionalmente, con radiacion ionizante, en el tratamiento de enfermedades asociadas con la angiogenesis y/o la permeabilidad vascular incrementada.
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
BRPI0516052A (pt) * 2004-09-27 2008-08-19 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
DE602006020621D1 (de) * 2005-12-22 2011-04-21 Astrazeneca Ab Kombination von zd6474 und pemetrexed
MX2008014953A (es) * 2006-05-26 2009-03-05 Bayer Healthcare Llc Combinaciones de medicamentos con diarilureas sustituidas para el tratamiento de cancer.
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
ES2444128T3 (es) * 2008-05-13 2014-02-24 Astrazeneca Ab Nueva SAL-554
WO2010061208A2 (en) * 2008-11-03 2010-06-03 Astrazeneca Ab Therapeutic treatment 555
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565478A (en) * 1994-03-14 1996-10-15 The United States Of America As Represented By The Department Of Health & Human Services Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs
DE69722793T2 (de) * 1996-04-26 2004-05-19 Genaera Corp. Squalamin in kombination mit anderen antikrebs-mittelen zur behandlung von tumoren
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9727524D0 (en) * 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
JP4808846B2 (ja) * 1999-02-24 2011-11-02 ザ ユーエイビー リサーチ ファンデイション 癌の標的付けられた治療のためのタキサン誘導体
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｖｅｇｆ 항체 및 이를 포함하는 약제학적 조성물
MXPA02004366A (es) * 1999-11-05 2002-11-07 Astrazeneca Ab Derivados de quinazolina como inhibidores vegf.
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
KR20050056190A (ko) * 2002-08-09 2005-06-14 아스트라제네카 아베 암의 치료에서의 방사선 요법과 함께 혈관 내피 성장 인자수용체의 억제제인 ｚｄ6474의 병행 치료
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
DK1592423T3 (da) * 2003-02-13 2011-06-27 Astrazeneca Ab Kombinationsterapi af ZD6474 med 5-FU og/eller CPT-11
MXPA06000114A (es) * 2003-07-10 2006-04-27 Astrazeneca Ab Uso del derivado de quinazolina zd6474 combinado con compuestos de platino y, opcionalmente, con radiacion ionizante, en el tratamiento de enfermedades asociadas con la angiogenesis y/o la permeabilidad vascular incrementada.
BRPI0516052A (pt) * 2004-09-27 2008-08-19 Astrazeneca Ab uso de zd6474 ou de um sal farmaceuticamente aceitável do mesmo e de imatinib, composição farmacêutica, kit, e, método para a produção de um efeito antiangiogênico e/ou de redução da permeabilidade vascular em um animal de sangue quente
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
DE602006020621D1 (de) * 2005-12-22 2011-04-21 Astrazeneca Ab Kombination von zd6474 und pemetrexed
US20100092466A1 (en) * 2006-09-29 2010-04-15 Anderson Joseph Ryan Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
NZ532525A (en) 2006-11-30
US20120252827A1 (en) 2012-10-04
NO328048B1 (no) 2009-11-16
BR0213906A (pt) 2004-08-31
ZA200403455B (en) 2005-08-29
EP1446124A1 (de) 2004-08-18
CA2464758C (en) 2010-09-28
DK1446124T3 (da) 2006-11-13
CY1106259T1 (el) 2011-06-08
AU2002337382B2 (en) 2008-06-12
DE60213845T2 (de) 2007-03-29
JP2005511597A (ja) 2005-04-28
CN1612738A (zh) 2005-05-04
JP4694127B2 (ja) 2011-06-08
ES2269769T3 (es) 2007-04-01
WO2003039551A1 (en) 2003-05-15
CN1298328C (zh) 2007-02-07
CA2464758A1 (en) 2003-05-15
KR100959607B1 (ko) 2010-05-27
MXPA04004355A (es) 2004-08-11
NO20042365L (no) 2004-06-07
US20050043395A1 (en) 2005-02-24
HK1068546A1 (en) 2005-04-29
KR20050043779A (ko) 2005-05-11
ATE335488T1 (de) 2006-09-15
IL161744A (en) 2012-01-31
PT1446124E (pt) 2006-12-29
EP1446124B1 (de) 2006-08-09
GB0126879D0 (en) 2002-01-02
IL161744A0 (en) 2005-11-20
AR037346A1 (es) 2004-11-03

Similar Documents

Publication Publication Date Title
DE60213845D1 (de) Kombinationstherapie mit zd6474 und einem taxan
DE60212600D1 (de) Audiocodierung und decodierung
DE60222285D1 (de) Niedrigviscose kratzresistente beschichtungen mit strukturgebenden und inorganischen füllstoffen
DE60308457D1 (de) Adaptive Modulation und Kodierung
DE60309190D1 (de) Magnetelement mit spintransfer und mram-bauelement mit dem magnetelement
ATE529375T1 (de) Zapfeinheit und behälter
EP1539941A4 (de) Adzyme und deren verwendungen
HK1086827A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
GB0116644D0 (en) Electroluminescent materials and devices
DE60228061D1 (de) Maschenware mit öffnung und herstellungsverfahren
AU2003256217A8 (en) New polymers and applications
PL369510A1 (en) Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
AU2003290341A8 (en) Electroluminescent materials and devices
DE60304229D1 (de) Pinselabflacher und mit Pinselabflacher ausgerüstete Zeichenvorrichtung
TW525651U (en) Posts with multi-directional jointing and lifting mechanisms
GB0228335D0 (en) Electroluminescent materials and devices
IL159872A0 (en) Gmg-2 polypeptides and their use
DE60223540D1 (de) Mundschutz und mundschutzfolie
AU2003298129A8 (en) Floor-furnace chimney and the use thereof
DE60203475D1 (de) Drosselklappe und Drossel
DE60238293D1 (de) Anschlussteil und Steckverbinder mit einem solchen Anschlussteil
DE60303601D1 (de) Abgabekopf und betätigungskopf mit einem solchen abgabekopf
AU2003298739A8 (en) Intermedin and its uses
AU2003302323A8 (en) A method and therapeutic platelets
PL363290A1 (en) 1k-polyurethane lacquer and use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition